What is the maximum recommended daily dose of QuilliChew (extended‑release methylphenidate) for a 9‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Dose of QuilliChew for a 9-Year-Old

The maximum recommended daily dose of QuilliChew ER for a 9-year-old is 60 mg once daily, as daily doses above 60 mg have not been studied and are not recommended. 1

FDA-Approved Dosing Parameters

The FDA label for QuilliChew ER is explicit and unambiguous about dosing limits 1:

  • Starting dose: 20 mg once daily in the morning
  • Titration: Weekly increments of 10 mg, 15 mg, or 20 mg based on efficacy and tolerability
  • Maximum dose: 60 mg daily (doses above this have not been studied and are not recommended)
  • Age indication: Approved for patients 6 years and above

Clinical Context and Supporting Evidence

While older methylphenidate guidelines reference a general maximum of 60 mg/day for immediate-release formulations 2, QuilliChew ER's specific formulation and extended-release mechanism require adherence to its product-specific maximum of 60 mg daily 1.

Weight-Based Considerations

For a typical 9-year-old (average weight ~30 kg), the 60 mg maximum dose translates to approximately 2 mg/kg/day. Historical guidelines suggest:

  • Children weighing less than 25 kg generally should not receive single doses greater than 15 mg of immediate-release methylphenidate 2
  • However, QuilliChew ER is a once-daily extended-release formulation with different pharmacokinetics than immediate-release products 1

Real-World Dosing Patterns

A 2018 open-label dose-optimization study of QuilliChew ER in children aged 6-12 years found 3:

  • Mean final optimized dose ranged from 40.0 mg/day (ages 6-8) to 44.8 mg/day (ages 11-12)
  • Final optimized doses ranged from 20-60 mg/day across all participants
  • Progressive improvement in ADHD symptoms occurred throughout titration

Important Clinical Caveats

Do not exceed 60 mg daily for the following reasons:

  1. Lack of safety and efficacy data: Doses above 60 mg have not been studied in clinical trials for QuilliChew ER 1

  2. Diminishing returns: Recent meta-analyses demonstrate a ceiling effect for methylphenidate efficacy, where dose escalation beyond licensed ranges offers minimal additional benefit while increasing adverse events 4

  3. Increased adverse event risk: The risk of discontinuation due to adverse events (sleep problems, decreased appetite, irritability) increases substantially at higher doses 4, 3

  4. Product-specific limitations: QuilliChew ER cannot be substituted milligram-per-milligram with other methylphenidate products due to different base compositions and pharmacokinetic profiles 1

Titration Algorithm

For a 9-year-old starting QuilliChew ER:

  1. Week 1: Start 20 mg once daily in the morning
  2. Week 2: Increase to 30 mg if inadequate response and good tolerability
  3. Week 3: Increase to 40 mg if needed
  4. Week 4: Increase to 50 mg if needed
  5. Week 5: Increase to 60 mg (maximum) only if clearly inadequate response at 50 mg and excellent tolerability

Stop titration when: Symptoms are adequately controlled with acceptable side effects, or when the maximum dose of 60 mg is reached 1.

When Maximum Dose Is Insufficient

If a 9-year-old does not respond adequately to 60 mg of QuilliChew ER after appropriate titration (typically 4-6 weeks), do not exceed 60 mg. Instead 2, 1:

  • Consider switching to an alternative methylphenidate formulation
  • Consider switching to an alternative stimulant (amphetamine-based)
  • Reassess the diagnosis and evaluate for comorbid conditions
  • Consider adding behavioral interventions or psychosocial treatments
  • Evaluate medication adherence and timing of administration

The principle "more is not necessarily better" applies—if the top recommended dose does not help, a change in drug or environmental intervention may be required rather than exceeding the maximum dose 2.

Related Questions

What are the recommended starting doses, titration increments, maximum daily doses, and safety monitoring for methylphenidate (immediate‑release and extended‑release) in children aged 6 years and older, adolescents, and adults with ADHD, as well as in adults and adolescents with narcolepsy?
What is the appropriate starting dose, titration schedule, maximum dose, monitoring parameters, and contraindications for methylphenidate extended‑release?
What are the differences among the available methylphenidate formulations (immediate‑release, sustained‑release, extended‑release, and transdermal) regarding onset of action, duration of effect, dosing schedule, and clinical use?
What is the maximum recommended daily dose of methylphenidate (immediate‑release and extended‑release) for children and adults?
What is an appropriate dose of methylphenidate extended-release solution for a 38‑lb (approximately 17 kg) pediatric patient?
What laboratory workup is indicated for a patient presenting with acute hyperglycemia?
What is the recommended management of insomnia in a blind patient?
What is the fraction of inspired oxygen (FiO₂) delivered by a nasal cannula at 3 L/min for a patient with acute respiratory acidosis, PaCO₂ 47 mm Hg and PaO₂ 50 mm Hg?
Can a patient transition from Latuda (lurasidone) to Caplyta (lumateperone) without tapering?
What is the mechanism of action of apixaban?
Which is a stronger muscle relaxant, cyclobenzaprine (Flexeril) or orphenadrine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.